Best Medications for Depression in Adults
Start with a second-generation antidepressant (SSRI or SNRI) as first-line pharmacotherapy for major depressive disorder in adults. 1, 2, 3
Recommended First-Line Antidepressants
The American College of Physicians guidelines establish that all second-generation antidepressants have equivalent efficacy, so selection should be based on adverse effect profiles, cost, and patient preferences 1.
Preferred SSRIs and SNRIs:
- Citalopram - favorable adverse effect profile, lower cost 4
- Escitalopram - favorable adverse effect profile 4
- Sertraline - appropriate choice, well-tolerated 4
- Venlafaxine - appropriate choice 4
- Bupropion - preferred when sexual dysfunction is a concern (lower rates than SSRIs) 1
- Mirtazapine - favorable adverse effect profile 4
Avoid in Older Adults:
- Paroxetine - higher anticholinergic effects 4
- Fluoxetine - greater risk of agitation and overstimulation 4
Critical Implementation Details
Begin monitoring within 1-2 weeks of starting medication for suicidal ideation, agitation, irritability, or unusual behavioral changes - suicide risk is highest in the first 1-2 months 1. SSRIs carry increased risk for suicide attempts compared to placebo 1.
Assess response at 6-8 weeks. If inadequate response, modify treatment 1. Approximately 38% of patients don't respond to initial treatment, and 54% don't achieve remission 1.
Treatment Duration
Continue for 4-9 months after first episode remission 1. For patients with 2+ prior episodes, continue indefinitely as recurrence risk escalates: 50% after first episode, 70% after second, 90% after third 4.
When Monotherapy Fails
For inadequate response to initial antidepressant, choose one strategy 3:
- Switch to different second-generation antidepressant
- Augment with second pharmacologic agent
- Add cognitive behavioral therapy
All switching and augmentation strategies show similar efficacy 5.
Combination Therapy Consideration
Combining cognitive behavioral therapy with antidepressant medication produces superior outcomes compared to either alone (effect size 0.30-0.33 better than monotherapy) 6. This is particularly important for moderate-to-severe or chronic depression 3.
Common Pitfalls
The evidence shows no single antidepressant is more effective than another 1, so avoid prolonged trials of multiple agents seeking "the right one" based on efficacy alone. Instead, switch based on tolerability issues or augment after 6-8 weeks of inadequate response.
Nausea and vomiting are the most common reasons for discontinuation 1. Bupropion specifically has lower sexual dysfunction rates than fluoxetine or sertraline 1.
Cost matters: Generic SSRIs cost $4-20/month versus $160-700 for brand names 4. When efficacy is equivalent, choose the most affordable tolerable option.